Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates

Hepatology Research

Volumn 41, Issue 12, 2011, Pages 1199-1207

  Yamashiki, Noriyo ^a   Sugawara, Yasuhiko ^a   Tamura, Sumihito ^a   Kaneko, Junichi ^a   Yoshida, Haruhiko ^a   Aoki, Taku ^a   Hasegawa, Kiyoshi ^a   Akahane, Masaaki ^a   Ohtomo, Kuni ^a   Fukayama, Masashi ^a   Koike, Kazuhiko ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatocellular carcinoma; Sensitivity and specificity; Tumor marker; Vitamin K deficiency

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DECARBOXYPROTHROMBIN; VITAMIN K GROUP;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INVASION; CANCER SCREENING; DIAGNOSTIC ACCURACY; END STAGE LIVER DISEASE; FEMALE; GENDER; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 82255185608     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00871.x     Document Type: Article

References (35)

1. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
3. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
4. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72 (Suppl 1): 2-15.
5. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310-12.
6. Yao FY, Ferrell L, Bass NM etal. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
7. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-9.
8. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
9. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008; 2: 17-30.
10. Aoyagi Y, Isemura M, Yosizawa Z etal. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta 1985; 830: 217-23.
11. Sato Y, Nakata K, Kato Y etal. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328: 1802-6.
12. Liebman HA, Furie BC, Tong MJ etal. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
13. Okuda H, Nakanishi T, Takatsu K etal. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85: 812-18.
14. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987; 4: 357-63.
15. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-8.
16. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-4.
17. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-18.
18. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
19. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 57-63.
20. Ishii M, Gama H, Chida N etal. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95: 1036-40.
21. Bechtold H, Andrassy K, Jahnchen E etal. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost 1984; 51: 358-61.
22. Creedon KA, Suttie JW. Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase. Thromb Res 1986; 44: 147-53.
23. Nishimura N, Usui Y, Kobayashi N, Okanoue T, Ozawa K, Vitamin K. menaquinone-4) metabolism in liver disease. Scand J Gastroenterol 1990; 25: 1089-96.
24. Shimizu K, Taniichi T, Satomura S, Matsuura S, Taga H, Taketa K. Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis. Clin Chim Acta 1993; 214: 3-12.
25. Kishi Y, Sugawara Y, Tamura S, Kaneko J, Kokudo N, Makuuchi M. Impact of incidentally found hepatocellular carcinoma on the outcome of living donor liver transplantation. Transpl Int 2006; 19: 720-5.
26. Fujiki M, Takada Y, Ogura Y etal. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-71.
27. Koike Y, Shiratori Y, Sato S etal. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
28. Nakagawa T, Seki T, Shiro T etal. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol 1999; 14: 281-6.
29. Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20: 215-19.
30. Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 2745-50.
31. Ohhira M, Ohtake T, Saito H etal. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res 1999; 23: 67S-70S.
32. Otsuka M, Kato N, Shao RX etal. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40: 243-51.
33. Murata K, Sakamoto A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2008; 33: 1149-55.
34. Mizuta T, Ozaki I, Eguchi Y etal. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006; 106: 867-72.
35. Taketomi A, Sanefuji K, Soejima Y etal. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531-7.